Tier 2 — strong

Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial

Anahid Rezaeifar, Mahtab Motamed, Niayesh Mohebbi
Human psychopharmacology 2026 41(4):e70057

Bibliography

PubMed
PMID 42438230
PubMed Central
PMC13358316
DOI
10.1002/hup.70057
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignRandomized triple-blind placebo-controlled trial
ModelHuman intervention research
Sample52 adults with autism spectrum disorder
InterventionOral quercetin versus placebo; dose not stated in abstract
Duration60 days
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2026, this source examined brain, cognition and sleep. Design: Randomized triple-blind placebo-controlled trial. Sample/model: 52 adults with autism spectrum disorder. The exposure or intervention was Oral quercetin versus placebo; dose not stated in abstract. Follow-up or treatment period: 60 days.

Social-responsiveness changes did not differ significantly between groups. An unadjusted physical quality-of-life signal lost significance after adjustment.

Small exploratory trial. Within-group improvement does not establish a treatment effect over placebo.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Social-responsiveness changes did not differ significantly between groups.
  • An unadjusted physical quality-of-life signal lost significance after adjustment.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Oral quercetin versus placebo; dose not stated in abstract; 60 days.

What this study can and cannot tell us

  • Small exploratory trial. Within-group improvement does not establish a treatment effect over placebo.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Two-month period of 500 mg lecithin-based delivery form of quercetin daily dietary supplementation counterbalances chronic fatigue symptoms: A double-blind placebo controlled clinical trial
Mariangela Rondanelli et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
Tier 2
Memory-Enhancing Effect of 8-Week Consumption of the Quercetin-Enriched Culinary Herbs-Derived Functional Ingredients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jintanaporn Wattanathorn et al. · Foods (Basel, Switzerland) · 2022
Tier 2
Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study
Y Nakamura et al. · European review for medical and pharmacological sciences · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology